Loading...

Aging Demographics And Modern Outpatient Demand Will Transform Value

Published
20 Mar 25
Updated
17 Oct 25
AnalystConsensusTarget's Fair Value
US$18.70
1.0% overvalued intrinsic discount
17 Oct
US$18.88
Loading
1Y
5.0%
7D
2.4%

Author's Valuation

US$18.71.0% overvalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on17 Oct 25
Fair value Increased 0.78%

Healthcare Realty Trust's analyst price target has been revised slightly upward to $18.70 from $18.56 as analysts factor in modest improvements in projected profit margin and discount rate, even though the outlook for revenue growth is marginally lower. What's in the News The company reported impairments of real estate assets totaling $140,877,000 for the second quarter ended June 30, 2025, up from $120,917,000 a year prior (Key Developments).

Shared on03 Oct 25
Fair value Increased 4.54%

Analysts have raised their price target for Healthcare Realty Trust from $17.75 to $18.56. They cite incremental improvements in fair value estimates based on modest adjustments to the discount rate and updated profit margin projections.

Shared on31 Aug 25
Fair value Increased 2.16%

The modest increase in Healthcare Realty Trust’s analyst price target reflects a slightly improved consensus revenue growth outlook, with fair value rising from $17.38 to $17.75. What's in the News No share repurchases made in Q2 2025; total buyback to date is 3,679,162 shares (1.03%) for $63.04 million.

Shared on01 May 25
Fair value Decreased 0.60%

Shared on24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 0.96%

AnalystConsensusTarget has increased revenue growth from -1.9% to -1.7%.

Shared on09 Apr 25
Fair value Increased 4.59%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 3.07%

Shared on26 Mar 25
Fair value Decreased 3.06%

AnalystConsensusTarget has increased revenue growth from -2.2% to -0.1%, decreased profit margin from 20.0% to 17.2%, increased future PE multiple from 27.4x to 32.1x and increased shares outstanding growth rate from -0.1% to -0.0%.